Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.41Zim Laboratories shows a mixed financial landscape. Revenue and asset growth are strong, alongside solid profitability driven by good gross profit and returns on assets and capital employed. The company maintains a strong equity position, indicating financial stability. However, liquidity is poor, with low current, quick, and cash ratios. Efficiency ratios are also weak, suggesting challenges in asset utilization. EPS and net income growth are concerning. While coverage ratios are mixed, with a reasonable interest coverage, the company does not distribute dividends. This overview suggests a need to address liquidity and efficiency while capitalizing on growth and profitability.
Health Score : 5.41Zim Laboratories shows a mixed financial landscape. Revenue and asset growth are strong, alongside solid profitability driven by good gross profit and returns on assets and capital employed. The company maintains a strong equity position, indicating financial stability. However, liquidity is poor, with low current, quick, and cash ratios. Efficiency ratios are also weak, suggesting challenges in asset utilization. EPS and net income growth are concerning. While coverage ratios are mixed, with a reasonable interest coverage, the company does not distribute dividends. This overview suggests a need to address liquidity and efficiency while capitalizing on growth and profitability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
106.25
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
108.20
P/B RATIO
2.13
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
1.82
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
16.67
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹117.94 as on Sep 1, 2026.
Growth Score : 6.00The company has strong revenue and asset growth. However, the negative earnings per share (EPS) growth and net income growth are concerning. The company's growth trajectory is promising in terms of revenue and assets, but profitability needs to catch up to ensure sustainable expansion.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 8.47 | 19.82 | -8.02 | 3.27 | -1.32 |
| Operating Profit Growth Rate | 2.5 | 26.83 | -21.15 | 7.32 | -31.82 |
| Earnings Per Share (EPS) Growth | 99.33 | 67.56 | -29.34 | -29.38 | -56.4 |
| Asset Growth Rate | 5.23 | 0 | 30.7 | 5.59 | 14.19 |
| Net Income Growth Rate | 114.29 | 60 | -29.17 | -29.41 | -50 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 2 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 3 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 4 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 5 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 60.35 | Neutral | 7.00 | 1.40 | 4.00 |
| 6 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 7 | BPL Ltd | 5.46 | -28.58 | Neutral | -4.82 | -1.69 | -8.55 |
| 8 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 9 | Quest Laboratories Ltd | 5.27 | 9.34 | Neutral | 18.00 | 9.16 | 15.00 |
| 10 | Sotac Pharmaceuticals Ltd | 5.27 | 17.25 | Neutral | 18.00 | 4.45 | 6.00 |
| 11 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 12 | Krebs Biochemicals & Industries Ltd | 4.16 | -4.36 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
| 13 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
| 14 | PANCHSHEEL | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Zim Laboratories is an India-based pharmaceutical company focused on developing, manufacturing, and marketing differentiated generic pharmaceutical products. It specializes in Oral Thin Films (OTF), pellets, and other specialized dosage forms, serving both domestic and international markets with a strong R&D focus and CDMO services.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Zim Laboratories Ltd's P/E ratio (TTM) is 106.25, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Zim Laboratories Ltd's P/B ratio is 2.13, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Zim Laboratories Ltd's P/S ratio is 1.82, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Zim Laboratories Ltd's PEG ratio is 1.40.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Zim Laboratories Ltd's EV/EBITDA ratio is 16.67.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Zim Laboratories Ltd's ROE is 2.02%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Zim Laboratories Ltd's ROA is 5.57%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Zim Laboratories Ltd's ROCE is 5%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Zim Laboratories Ltd's operating margin is 8.02%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Zim Laboratories Ltd's net margin is 1.60%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Zim Laboratories Ltd's current ratio is 1.43.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Zim Laboratories Ltd's debt-to-equity ratio is 0.15.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Zim Laboratories Ltd's interest coverage ratio is 1.62.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Zim Laboratories Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Zim Laboratories Ltd's EPS is -56.40.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹117.94. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1989
Headquarters: Nagpur, Maharashtra
Core Offerings: Oral Thin Films, Pellets and Granules, Tablets and Capsules, Contract Manufacturing (CDMO)
Stock Listing: NSE (ZIMLAB), BSE (541400)
Promoter: Dr. Anwar Daud and family
1989: Incorporated as Zim Laboratories Limited. 1992: Commenced commercial production of pharmaceutical products. Early 2000s: Expanded into specialized dosage forms and started focusing on regulated markets. 2010s: Intensified R&D efforts in Oral Thin Films (OTF) technology and CDMO services, gaining global regulatory approvals. Present: Established as a specialized pharma player with a significant presence in advanced drug delivery systems globally.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Oral Thin Films (OTF) | Significant contribution, not explicitly disclosed | Operating Profit |
| Pellets and Granules | Significant contribution, not explicitly disclosed | Operating Profit |
| Other Finished Dosage Forms | Contribution, not explicitly disclosed | Operating Profit |
| Contract Development & Manufacturing Organization (CDMO) | Growing contribution, not explicitly disclosed | Operating Profit |
Oral Thin Films (OTFs): Specializes in developing and manufacturing innovative drug delivery systems, offering better patient compliance, faster onset of action, and improved bioavailability across various therapeutic areas.
Pellets and Granules: Offers a wide range of modified-release pellets, sustained-release pellets, and customized granules for diverse pharmaceutical applications, including niche and complex molecules.
Contract Development & Manufacturing Organization (CDMO): Provides end-to-end services from product development to commercial manufacturing for various dosage forms, leveraging its specialized technologies and regulatory expertise for global clients.
Dr. Anwar Daud - Chairman & Managing Director. A visionary entrepreneur and technocrat with over three decades of experience, he founded Zim Laboratories and has been instrumental in driving its innovation and strategic direction in specialized drug delivery.
No major subsidiaries reported.
2023: Bonus Issue (1:2). 2021: Rights Issue.
The Zim Laboratories Ltd share price today is ₹117.94 on NSE (ZIMLAB), as of 26 Sept 2026.
As of 25 Sept 2026, Zim Laboratories Ltd share price is ₹117.94, with previous close ₹117.94. Today's range is ₹117.94 to ₹117.94. The 52-week range is ₹59.31 to ₹144.49.
As of today, Zim Laboratories Ltd's market cap is ₹680.51 crore (Small Cap).
Zim Laboratories Ltd's current P/E ratio is 106.25, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 32.50.
Zim Laboratories Ltd's current P/B ratio is 2.13.
Zim Laboratories Ltd's current dividend yield is N/A. Last dividend of ₹0.50 per share was declared on 30-May-2023.
Zim Laboratories Ltd's EPS (TTM) is ₹-56.40.
Zim Laboratories is an India-based pharmaceutical company focused on developing, manufacturing, and marketing differentiated generic pharmaceutical products. It specializes in Oral Thin Films (OTF), pellets, and other specialized dosage forms, serving both domestic and international markets with a strong R&D focus and CDMO services.
Zim Laboratories Ltd is promoted by Dr. Anwar Daud and family, holding 30.35% as of 25 Sept 2026.
Zim Laboratories Ltd is listed on NSE (ZIMLAB) and BSE (541400). Its next quarterly results are expected on May 2024.
